ストックスクリーナーアプリを入手
11.06
0.50%
0.00
前日終値:
$11.06
開ける：
$11
24時間の取引高:
106.55K
Relative Volume:
0.10
時価総額：
$872.30M
収益：
$147.19M
当期純損益:
$-274.55M
株価収益率:
-2.9007
EPS:
-3.8129
ネットキャッシュフロー:
$-225.38M
1週間 パフォーマンス:
-18.03%
1か月 パフォーマンス:
-10.44%
6か月 パフォーマンス:
-9.93%
1年 パフォーマンス:
+82.81%
1日の値動き範囲:
$10.89
$11.24
1週間の範囲:
$10.69
$13.76
52週間の値動き範囲:
$2.21
$18.31
Phathom Pharmaceuticals Inc Stock (PHAT) Company Profile
名前
Phathom Pharmaceuticals Inc
セクター
電話
(877) 742-8466
住所
100 CAMPUS DRIVE,, FLORHAM PARK, NJ
Compare PHAT vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PHAT
Phathom Pharmaceuticals Inc
|
11.07 | 871.51M | 147.19M | -274.55M | -225.38M | -3.8129 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.94 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
774.57 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
731.68 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
323.49 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
295.38 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Phathom Pharmaceuticals Inc Stock (PHAT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-12 | 開始されました | Raymond James | Strong Buy |
| 2025-12-09 | 開始されました | Barclays | Equal Weight |
| 2025-02-14 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-05-03 | 開始されました | Stifel | Buy |
| 2024-01-05 | 繰り返されました | Needham | Buy |
| 2023-08-09 | 開始されました | H.C. Wainwright | Buy |
| 2023-05-11 | アップグレード | Evercore ISI | In-line → Outperform |
| 2023-03-13 | 開始されました | Craig Hallum | Buy |
| 2022-10-21 | 開始されました | Jefferies | Buy |
| 2022-05-06 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2021-05-12 | アップグレード | Goldman | Sell → Neutral |
| 2021-02-17 | 開始されました | BMO Capital Markets | Outperform |
| 2021-02-02 | 開始されました | Guggenheim | Buy |
| 2020-06-26 | ダウングレード | Goldman | Neutral → Sell |
| 2019-11-20 | 開始されました | Evercore ISI | Outperform |
| 2019-11-19 | 開始されました | Goldman | Neutral |
| 2019-11-19 | 開始されました | Jefferies | Buy |
| 2019-11-19 | 開始されました | Needham | Buy |
すべてを表示
Phathom Pharmaceuticals Inc (PHAT) 最新ニュース
Propel Bio Management LLC Sells 370,000 Shares of Phathom Pharmaceuticals, Inc. $PHAT - MarketBeat
Phathom Pharmaceuticals Charts Profitable Path After Ramp-Up - TipRanks
PHAT Technical Analysis & ETF Price Forecast - Intellectia AI
Phathom (PHAT) accounting chief gets RSUs, surrenders shares for tax - Stock Titan
PHAT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Phathom (PHAT) Q4 2025 Earnings Call Transcript - AOL.com
Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Down 6.5%Should You Sell? - MarketBeat
Helicobacter pylori Infection Market: Accelerating Growth and Pipeline Impact by 2034 – DelveInsight | RedHill Biopharma, Phathom Pharma, Takeda Pharma, Otsuka Pharma, Juvisé Pharma, AbbVie, TenNor - Barchart.com
Guggenheim Raises PT on Phathom Pharmaceuticals (PHAT) to $25 From $20, Here’s Why - Insider Monkey
Guggenheim Raises PT on Phathom Pharmaceuticals (PHAT) to $25 From $20, Here's Why - Bitget
Phathom Pharmaceuticals: Early VOQUEZNA Traction, Strengthened Balance Sheet, and Clear Path to Profitability Support Buy Rating - TipRanks
Phathom Pharmaceuticals (NASDAQ:PHAT) Posts Earnings Results, Beats Expectations By $0.01 EPS - MarketBeat
Why Phathom Pharmaceuticals (PHAT) Is Up 13.2% After Guiding To 2026 Operating Profitability And Narrower Losses - Yahoo Finance
Guggenheim Raises Price Target for Phathom Pharmaceuticals (PHAT) to $25 | PHAT Stock News - GuruFocus
Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Expected to Rise, Guggenheim Analyst Says - MarketBeat
Phathom Pharmaceuticals Hits Day High with 10.06% Surge in Stock Price - Markets Mojo
Phathom Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q4 2025 Earnings Call Transcript - Insider Monkey
Phathom Pharmaceuticals, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:PHAT) 2026-02-27 - Seeking Alpha
Phathom Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
Decoding Phathom Pharmaceuticals Inc (PHAT): A Strategic SWOT In - GuruFocus
Phathom Pharmaceuticals Inc (PHAT) Q4 2025 Earnings Call Highlig - GuruFocus
Phathom Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Phathom Pharmaceuticals (PHAT) Stock Analysis: A Look At Its 85.88% Potential Upside - DirectorsTalk Interviews
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
Phathom Pharmaceuticals (NASDAQ:PHAT) Trading Up 14.3% on Earnings Beat - MarketBeat
Earnings call transcript: Phathom Pharmaceuticals Q4 2025 beats expectations, stock surges - Investing.com Nigeria
Phathom Pharmaceuticals Shares Rise After Q4 Loss Narrows, Revenue Rises - marketscreener.com
Phathom Q4 2025 slides: 217% revenue growth, profitability in sight By Investing.com - Investing.com UK
Earnings Flash (PHAT) Phathom Pharmaceuticals, Inc. Posts Q4 Adjusted Loss $0.08 per Share, vs. FactSet Est of $-0.20 - marketscreener.com
Earnings Flash (PHAT) Phathom Pharmaceuticals, Inc. Reports Q4 Revenue $57.6M, vs. FactSet Est of $57.2M - marketscreener.com
PHATHOM PHARMA ($PHAT) Releases Q4 2025 Earnings - Quiver Quantitative
Phathom Pharma earnings beat by $0.34, revenue topped estimates - Investing.com UK
Phathom Pharmaceuticals : Fourth Quarter 2025 Earnings Call Presentation – February 2026 - marketscreener.com
Phathom Pharmaceuticals Q4 revenue slightly beats expectations - TradingView
Phathom Pharmaceuticals, Inc. SEC 10-K Report - TradingView
Phathom Pharmaceuticals (PHAT) grows 2025 sales but remains deeply unprofitable - Stock Titan
Phathom Pharmaceuticals Earnings Review: Q4 Summary - Benzinga
BRIEF-Phathom Pharmaceuticals Q4 Net Income USD -21.148 Million - TradingView
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance - Yahoo Finance
Phathom Pharmaceuticals Q4 2025 Earnings Call Transcript - MarketBeat
Phathom Pharmaceuticals, Inc. (PHAT) Posts Fourth Quarter Loss, Surpasses Revenue Projections - Bitget
What To Expect From Phathom Pharmaceuticals Inc (PHAT) Q4 2025 E - GuruFocus
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewswire
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Phathom Pharmaceuticals (PHAT) to Release Quarterly Earnings on Thursday - MarketBeat
Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Down 6%Time to Sell? - MarketBeat
Wall Street Analysts See a 66.13% Upside in Phathom Pharmaceuticals (PHAT): Can the Stock Really Move This High? - MSN
Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, February 26, 2026 - The Manila Times
Drugmaker Phathom to break down 2025 results, update in Feb. 26 webcast - Stock Titan
Breakout Watch: Does Phathom Pharmaceuticals Inc have strong fundamentalsTrade Volume Summary & Comprehensive Market Scan Insights - baoquankhu1.vn
Phathom Pharmaceuticals Inc (PHAT) 財務データ
収益
当期純利益
現金流量
EPS
Phathom Pharmaceuticals Inc (PHAT) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Parikh Asit | Director |
Dec 19 '25 |
Option Exercise |
10.30 |
8,750 |
90,125 |
122,250 |
| Basta Steven L | President and CEO |
Nov 28 '25 |
Option Exercise |
0.00 |
90,000 |
0 |
131,625 |
| Breedlove Robert Charles | Principal Accounting Officer |
Nov 03 '25 |
Sale |
13.51 |
524 |
7,079 |
47,407 |
| Basta Steven L | President and CEO |
Sep 25 '25 |
Option Exercise |
0.00 |
90,000 |
0 |
90,000 |
| Breedlove Robert Charles | Principal Accounting Officer |
Sep 05 '25 |
Sale |
12.09 |
461 |
5,573 |
47,931 |
| Breedlove Robert Charles | Principal Accounting Officer |
Jul 16 '25 |
Sale |
8.36 |
1,692 |
14,152 |
48,392 |
| Topper James N | Director |
May 21 '25 |
Buy |
3.86 |
3,780 |
14,609 |
59,403 |
| Topper James N | Director |
May 14 '25 |
Buy |
3.32 |
6,300 |
20,919 |
55,623 |
| Topper James N | Director |
May 13 '25 |
Buy |
3.16 |
1,120 |
3,543 |
49,323 |
| Topper James N | Director |
May 09 '25 |
Buy |
3.22 |
35,602 |
114,616 |
35,602 |
0.50%
大文字化:
|
ボリューム (24 時間):